Short Interest in Yarrow Bioscience (NASDAQ:YARW) Grows By 190.8%

Yarrow Bioscience (NASDAQ:YARW) saw a significant growth in short interest in August. As of August 31st, there was short interest totaling 56,499 shares, a growth of 190.8% from the August 15th total of 19,427 shares. Currently, 2.2% of the company’s stock are sold short. Based on an average daily trading volume, of 46,917 shares, the short-interest ratio is presently 1.2 days.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. BTIG Research assumed coverage on shares of Yarrow Bioscience in a research report on Monday, August 3rd. They set a “buy” rating and a $58.00 price target for the company. TD Cowen initiated coverage on shares of Yarrow Bioscience in a research report on Tuesday, July 28th. They issued a “buy” rating on the stock. Finally, Wall Street Zen upgraded shares of Yarrow Bioscience to a “hold” rating in a research note on Saturday, August 22nd. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $58.00.

Yarrow Bioscience Stock Performance

Shares of NASDAQ YARW opened at $27.01 on Friday. Yarrow Bioscience has a 52 week low of $14.68 and a 52 week high of $46.95. The company has a market capitalization of $72.12 million, a P/E ratio of -1.84 and a beta of 2.01.

Yarrow Bioscience (NASDAQ:YARW) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($3.51) EPS for the quarter, missing the consensus estimate of ($0.18) by ($3.33). The business had revenue of $0.10 million during the quarter, compared to analysts’ expectations of $0.20 million. Yarrow Bioscience had a negative net margin of 4,726.21% and a negative return on equity of 84.40%.

Yarrow Bioscience Dividend Announcement

The firm also recently disclosed a special dividend, which was paid on Thursday, July 23rd. Stockholders of record on Wednesday, July 22nd were given a $19.00 dividend.

Hedge Funds Weigh In On Yarrow Bioscience

A number of large investors have recently added to or reduced their stakes in the stock. Two Sigma Securities LLC purchased a new stake in shares of Yarrow Bioscience during the second quarter worth about $26,000. BlackRock Inc. purchased a new position in Yarrow Bioscience in the 2nd quarter valued at about $29,000. GSA Capital Partners LLP acquired a new stake in Yarrow Bioscience in the 2nd quarter worth about $47,000. XTX Topco Ltd acquired a new stake in Yarrow Bioscience in the 4th quarter worth about $46,000. Finally, Boothbay Fund Management LLC acquired a new stake in Yarrow Bioscience in the 2nd quarter worth about $176,000. 83.78% of the stock is currently owned by institutional investors and hedge funds.

Yarrow Bioscience Company Profile

VYNE Therapeutics Inc, a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2.